Ardsley Advisory Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Ardsley Advisory Partners’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-260,000	Closed	-$3.84M	–	191
2020 Q2	$3.84M	Buy	260,000 +30,000	+13%	+$444K	0.82%	34
2020 Q1	$3.1M	Buy	230,000 +75,000	+48%	+$1.42M	1.22%	27
2019 Q4	$3.75M	Buy	+155,000	New	+$3.21M	0.6%	39

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Ardsley Advisory Partners's AERI Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of Aerie Pharmaceuticals (AERI) in Q3 2020, closing a stake of 260,000 shares — an estimated $3.84M sold.

Ardsley Advisory Partners first reported a position in AERI in Q4 2019 and held it in 3 quarters. The position peaked at $3.84M in Q2 2020. 148 funds tracked by Wall St. Rank hold AERI as of Q3 2020.

Ardsley Advisory Partners reported no remaining Aerie Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 260,000 Aerie Pharmaceuticals shares in Q3 2020, an estimated $3.84M.
Ardsley Advisory Partners first reported a position in Aerie Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Ardsley Advisory Partners's Aerie Pharmaceuticals position peaked at $3.84M in Q2 2020.
148 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.